Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts
- DPI2954445
- 105 Pages
- February 2019
- Pharmaceuticals
“Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscape, and discusses major trends. The report offers the most up-to-date industry data on the actual market situation, and future outlook for global human immunodeficiency virus (HIV) drugs market. The report includes historical data from 2015 to 2018, and forecasts until 2025.
The report contains a granular analysis of the present industry situations, market demands, reveals facts on the market size, revenues and provides forecasts through 2025. The report provides clear insight into current and future developments of the global human immunodeficiency virus (HIV) drugs market. The report explores detailed analysis of top 22 HIV drugs market assessment globally from 2015 to 2018 and forecasts to 2025. The report also details the latest happenings about the global research & development of HIV drugs.
Additionally, the report includes an assessment of clinical trials and promising human immunodeficiency virus (HIV) drugs in clinical development. Key trends in terms of collaboration, partnerships, and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the global human immunodeficiency virus (HIV) drugs market.
The report concludes with the profiles of major players in the global human immunodeficiency virus (HIV) drugs market. The key market players are evaluated on various parameters such as business overview and recent development.
The Major Companies Dominating this Market for its Drugs, Services and Continuous Drugs Developments are:
• AbbVie
• Merck
• Gilead Sciences
• Bristol–Myers Squibb
• Janssen (Johnson&Johnson)
• GlaxoSmithKline (GSK)
Top 22 Human Immunodeficiency Virus (HIV) Drugs Covered Under this Report are:
• Tivicay
• Triumeq
• Juluca
• Epzicom
• Selzentry
• Kaletra
• Sustiva
• Reyataz
• Atripla
• Truvada
• Viread
• Complera
• Stribild
• Genvoya
• Biktarvy
• Descovy
• Odefsey
• Prezista/Prezcobix
• Edurant
• Isentress
• Pifeltro
• Delstrigo
The Latest Industry Data Included in this Report:
• Global HIV Drugs Market Size & Analysis (2015 – 2025)
• Global HIV Drugs Market Share & Y-o-Y Growth (%),2015 – 2025
• Global Top 22 HIV Drugs Market Assessment & Opportunity (2015 – 2025)
• Promising HIV Drugs in Clinical Development
• HIV Drugs Clinical Trial Insight by Phase, Institute & Country,2018
• Major Deals (Key Agreements, Partnerships & Collaborations)
• Latest Happenings in Global HIV Drugs Market
• Key Drivers & Inhibitors of the Global HIV Drugs Market
• Major Companies Analysis
The Answers to the Following Key Questions can be found in the Report:
• What is the size of the global HIV drugs market during 2015 -2025?
• What will be the revenue generated by each drug during the forecast period?
• Which major drug provides the highest market share?
• How are the overall market and major drugs growing?
• What are the key drivers and inhibitors in the current market?
• What will be the impact of drivers and inhibitors in the future?
• How is the market predicted to develop in the future?
• Who are the key players in this market space?
2. Global HIV Drugs Market Size & Analysis (2015 – 2025)
3. Global HIV Drugs Market Share & Y-o-Y Growth (%),2015 – 2025
4. Latest Happenings in Global HIV Drugs Market
5. Key Drivers & Inhibitors of the Global HIV Drugs Market
5.1 Market Drivers
5.2 Inhibitors
6. Global Top 22 HIV Drugs Market Assessment & Opportunity (2015 – 2025)
6.1 Tivicay (dolutegravir)
6.2 Triumeq (dolutegravir/abacavir/lamivudine)
6.3 Juluca (dolutegravir and rilpivirine)
6.4 Epzicom (abacavir and lamivudine)
6.5 Selzentry (maraviroc)
6.6 Kaletra (Iopinavir/ritonavir)
6.7 Sustiva (efavirenz)
6.8 Reyataz (atazanavir)
6.9 Atripla (efavirenz/emtricitabine/tenofovir)
6.10 Truvada (emtricitabine/tenofovir disoproxil fumarate)
6.11 Viread (tenofovir disoproxil fumarate)
6.12 Complera (emtricitabine, rilpivirine, and tenofovir disoproxil fumarate)
6.13 Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
6.14 Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
6.15 Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide)
6.16 Descovy (emtricitabine and tenofovir alafenamide)
6.17 Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide)
6.18 Prezista/Prezcobix (darunavir ethanolate /cobicistat)
6.19 Edurant (rilpivirine)
6.20 Isentress (raltegravir)
6.21 Pifeltro (doravirine)
6.22 Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate)
7. Partnerships, Collaboration & Licensing Agreement in Global HIV Drugs Market
8. Promising HIV Drugs in Clinical Development
9. HIV Drugs Clinical Trial Insight by Phase, Institute & Country,2018
10. Key Companies Analysis
10.1 AbbVie
10.1.1 Business Overview
10.1.2 Recent Development
10.2 GlaxoSmithKline (GSK)
10.2.1 Business Overview
10.2.2 Recent Development
10.3 Gilead Sciences
10.3.1 Business Overview
10.3.2 Recent Development
10.4 Merck
10.4.1 Business Overview
10.4.2 Recent Development
10.5 Bristol Myers Squibb
10.5.1 Business Overview
10.5.2 Recent Development
10.6 Janssen (Johnson & Johnson)
10.6.1 Business Overview
10.6.2 Recent Development
Table 3–2: Global HIV Drugs Market Share & Y–o–Y Growth Forecast (%), 2019 – 2025
Table 7–1: Partnerships, Collaboration & Licensing Agreement in Global HIV Drugs Market
Similar Reports
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
- Publish Date: November 14, 2017
- $5370
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
- Publish Date: July 20, 2017
- $5370
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...
- Publish Date: April 24, 2017
- $5370
